Age-related macular degeneration
Conditions
Interventions
Eylea (aflibercept) Lucentis(ranibizumab) Macugen(Pegaptanib sodium)
Sponsors
Department of Ophthalmology, Kagawa university faculty of medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) BCVA: 0.1-1.0 2) AMD with subfoveal fluid on fluorescent angiography, indocyanine green angiography and/or optical coherence tomography 3) Willingness to provide written informed consent 4) outpatient
Exclusion criteria
Exclusion criteria: 1) Greatest Linear Dimension (GLD) of the total lesion area <12 Macular Photocoagulation Study Disc Areas 2) Presence of subretinal hemorrhage, scar or macular fibrosis (>50% lesion area) 3) Prior treatment with anti-VEGF drug, photodynamic therapy 4) Prior treatment with dexamethasone (<6 months) or triamcinolone (<30 days), intraocular surgery (<3 months) 5) Active intraocular inflammation 6) Hypersensitivity or allergy to fluorescein or indocyanine green, clinically significant drug allergy or known hypersensitivity to therapeutic or diagnostic protein products 7) Patient who the doctor in charge judges are ineligible for the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change of visual acuity at month 12,24,36. | — |
Secondary
| Measure | Time frame |
|---|---|
| The average treatment number according to the medicine , central macular thickness, change of leakage in retinal region, leakage from a polyp, leakage from choroidal neovascularization, subretinal fluid , the rate of incident and the enlargement of the geographic atrophy | — |
Countries
Japan
Contacts
Public ContactRie Osaka
Kagawa university faculty of medicine Department of Ophthalmology
Outcome results
None listed